{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T08:28:36Z","timestamp":1794644916018,"version":"4.9.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13054-016-1320-7","type":"journal-article","created":{"date-parts":[[2016,5,4]],"date-time":"2016-05-04T15:47:33Z","timestamp":1462376853000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":240,"title":["Antibiotic strategies in the era of multidrug resistance"],"prefix":"10.1186","volume":"20","author":[{"given":"George","family":"Karam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Chastre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H.","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,22]]},"reference":[{"key":"1320_CR1","unstructured":"European Center for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2014. http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/antimicrobial-resistance-europe-2014.pdf . Accessed 4 Apr 2016."},{"key":"1320_CR2","unstructured":"European Center for Disease Prevention and Control. Carbapenemase-producing bacteria in Europe. http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/antimicrobial-resistance-carbapenemase-producing-bacteria-europe.pdf . Accessed 4 Apr 2016."},{"key":"1320_CR3","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1473-3099(13)70190-7","volume":"13","author":"LS Munoz-Price","year":"2013","unstructured":"Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13:785\u201396.","journal-title":"Lancet Infect Dis"},{"key":"1320_CR4","unstructured":"US Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. http:\/\/www.cdc.gov\/drugresistance\/threat-report-2013\/pdf\/ar-threats-2013-508.pdf . Accessed 4 Apr 2016."},{"key":"1320_CR5","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","volume":"18","author":"DL Paterson","year":"2005","unstructured":"Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18:657\u201386.","journal-title":"Clin Microbiol Rev"},{"key":"1320_CR6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.7326\/0003-4819-140-1-200401060-00008","volume":"140","author":"DL Paterson","year":"2004","unstructured":"Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med. 2004;140:26\u201332.","journal-title":"Ann Intern Med"},{"key":"1320_CR7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1086\/498519","volume":"42","author":"J Rodriguez-Bano","year":"2006","unstructured":"Rodriguez-Bano J, Navarro MD, Romero L, Muniain MA, Perea EJ, Perez-Cano R, et al. Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control. Clin Infect Dis. 2006;42:37\u201345.","journal-title":"Clin Infect Dis"},{"key":"1320_CR8","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1093\/infdis\/154.5.792","volume":"154","author":"CC Sanders","year":"1986","unstructured":"Sanders CC, Sanders Jr WE. Type I beta-lactamases of Gram-negative bacteria: interactions with beta-lactam antibiotics. J Infect Dis. 1986;154:792\u2013800.","journal-title":"J Infect Dis"},{"key":"1320_CR9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1473-3099(15)00424-7","volume":"16","author":"YY Liu","year":"2016","unstructured":"Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16:161\u20138.","journal-title":"Lancet Infect Dis"},{"key":"1320_CR10","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1128\/CMR.00001-07","volume":"20","author":"AM Queenan","year":"2007","unstructured":"Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev. 2007;20:440\u201358.","journal-title":"Clin Microbiol Rev"},{"key":"1320_CR11","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s00239-002-2328-y","volume":"55","author":"M Barlow","year":"2002","unstructured":"Barlow M, Hall BG. Phylogenetic analysis shows that the OXA beta-lactamase genes have been on plasmids for millions of years. J Mol Evol. 2002;55:314\u201321.","journal-title":"J Mol Evol"},{"key":"1320_CR12","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nature10388","volume":"477","author":"VM D'Costa","year":"2011","unstructured":"D'Costa VM, King CE, Kalan L, Morar M, Sung WW, Schwarz C, et al. Antibiotic resistance is ancient. Nature. 2011;477:457\u201361.","journal-title":"Nature"},{"key":"1320_CR13","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1128\/AAC.01823-12","volume":"57","author":"L Armand-Lefevre","year":"2013","unstructured":"Armand-Lefevre L, Angebault C, Barbier F, Hamelet E, Defrance G, Ruppe E, et al. Emergence of imipenem-resistant Gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother. 2013;57:1488\u201395.","journal-title":"Antimicrob Agents Chemother"},{"key":"1320_CR14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2334-14-13","volume":"14","author":"BG Bell","year":"2014","unstructured":"Bell BG, Schellevis F, Stobberingh E, Goossens H, Pringle M. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infect Dis. 2014;14:13.","journal-title":"BMC Infect Dis"},{"key":"1320_CR15","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ijmm.2013.04.004","volume":"303","author":"E Meyer","year":"2013","unstructured":"Meyer E, Gastmeier P, Deja M, Schwab F. Antibiotic consumption and resistance: data from Europe and Germany. Int J Med Microbiol. 2013;303:388\u201395.","journal-title":"Int J Med Microbiol"},{"issue":"Suppl 3","key":"1320_CR16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1469-0691.2009.02725.x","volume":"15","author":"H Goossens","year":"2009","unstructured":"Goossens H. Antibiotic consumption and link to resistance. Clin Microbiol Infect. 2009;15 Suppl 3:12\u20135.","journal-title":"Clin Microbiol Infect"},{"key":"1320_CR17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0140-6736(05)70799-6","volume":"365","author":"H Goossens","year":"2005","unstructured":"Goossens H, Ferech M, Vander SR, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005;365:579\u201387.","journal-title":"Lancet"},{"key":"1320_CR18","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S1473-3099(13)70318-9","volume":"13","author":"R Laxminarayan","year":"2013","unstructured":"Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, et al. Antibiotic resistance\u2014the need for global solutions. Lancet Infect Dis. 2013;13:1057\u201398.","journal-title":"Lancet Infect Dis"},{"key":"1320_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vetmic.2014.01.013","volume":"170","author":"L Garcia-Migura","year":"2014","unstructured":"Garcia-Migura L, Hendriksen RS, Fraile L, Aarestrup FM. Antimicrobial resistance of zoonotic and commensal bacteria in Europe: the missing link between consumption and resistance in veterinary medicine. Vet Microbiol. 2014;170:1\u20139.","journal-title":"Vet Microbiol"},{"key":"1320_CR20","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0140-6736(07)60235-9","volume":"369","author":"S Malhotra-Kumar","year":"2007","unstructured":"Malhotra-Kumar S, Lammens C, Coenen S, Van Herck K, Goossens H. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet. 2007;369:482\u201390.","journal-title":"Lancet"},{"key":"1320_CR21","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1086\/344654","volume":"36","author":"DM Livermore","year":"2003","unstructured":"Livermore DM. Bacterial resistance: origins, epidemiology, and impact. Clin Infect Dis. 2003;36:S11\u201323.","journal-title":"Clin Infect Dis"},{"key":"1320_CR22","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ijmm.2013.02.004","volume":"303","author":"A Rodriguez-Rojas","year":"2013","unstructured":"Rodriguez-Rojas A, Rodriguez-Beltran J, Couce A, Blazquez J. Antibiotics and antibiotic resistance: a bitter fight against evolution. Int J Med Microbiol. 2013;303:293\u20137.","journal-title":"Int J Med Microbiol"},{"key":"1320_CR23","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1086\/381550","volume":"38","author":"E Paramythiotou","year":"2004","unstructured":"Paramythiotou E, Lucet JC, Timsit JF, Vanjak D, Paugam-Burtz C, Trouillet JL, et al. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis. 2004;38:670\u20137.","journal-title":"Clin Infect Dis"},{"key":"1320_CR24","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.diagmicrobio.2011.03.009","volume":"70","author":"Y Carmeli","year":"2011","unstructured":"Carmeli Y, Lidji SK, Shabtai E, Navon-Venezia S, Schwaber MJ. The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study. Diagn Microbiol Infect Dis. 2011;70:367\u201372.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1320_CR25","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1086\/649554","volume":"50","author":"JS Solomkin","year":"2010","unstructured":"Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:133\u201364.","journal-title":"Clin Infect Dis"},{"key":"1320_CR26","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","volume":"171","author":"Amercian Thoracic Society, Infectious Diseases Society of America","year":"2005","unstructured":"Amercian Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388\u2013416.","journal-title":"Am J Respir Crit Care Med"},{"key":"1320_CR27","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/jac\/dkr156","volume":"66","author":"N Patel","year":"2011","unstructured":"Patel N, Harrington S, Dihmess A, Woo B, Masoud R, Martis P, et al. Clinical epidemiology of carbapenem-intermediate or -resistant Enterobacteriaceae. J Antimicrob Chemother. 2011;66:1600\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"1320_CR28","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/jac\/dkr116","volume":"66","author":"EI Kritsotakis","year":"2011","unstructured":"Kritsotakis EI, Tsioutis C, Roumbelaki M, Christidou A, Gikas A. Antibiotic use and the risk of carbapenem-resistant extended-spectrum-\u03b2-lactamase-producing Klebsiella pneumoniae infection in hospitalized patients: results of a double case-control study. J Antimicrob Chemother. 2011;66:1383\u201391.","journal-title":"J Antimicrob Chemother"},{"key":"1320_CR29","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1086\/498909","volume":"193","author":"A Kumar","year":"2006","unstructured":"Kumar A, Haery C, Paladugu B, Kumar A, Symeoneides S, Taiberg L, et al. The duration of hypotension before the initiation of antibiotic treatment is a critical determinant of survival in a murine model of Escherichia coli septic shock: association with serum lactate and inflammatory cytokine levels. J Infect Dis. 2006;193:251\u20138.","journal-title":"J Infect Dis"},{"key":"1320_CR30","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1097\/CCM.0000000000000330","volume":"42","author":"R Ferrer","year":"2014","unstructured":"Ferrer R, Martin-Loeches I, Phillips G, Osborn TM, Townsend S, Dellinger RP, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med. 2014;42:1749\u201355.","journal-title":"Crit Care Med"},{"issue":"Suppl 4","key":"1320_CR31","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1086\/382690","volume":"38","author":"DL Paterson","year":"2004","unstructured":"Paterson DL. \u201cCollateral damage\u201d from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis. 2004;38 Suppl 4:S341\u20135.","journal-title":"Clin Infect Dis"},{"key":"1320_CR32","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1056\/NEJMra041359","volume":"352","author":"GA Jacoby","year":"2005","unstructured":"Jacoby GA, Munoz-Price LS. The new beta-lactamases. N Engl J Med. 2005;352:380\u201391.","journal-title":"N Engl J Med"},{"key":"1320_CR33","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/cid\/cir790","volume":"54","author":"J Rodriguez-Bano","year":"2012","unstructured":"Rodriguez-Bano J, Navarro MD, Retamar P, Picon E, Pascual A. beta-Lactam\/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis. 2012;54:167\u201374.","journal-title":"Clin Infect Dis"},{"key":"1320_CR34","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/cid\/civ003","volume":"60","author":"PD Tamma","year":"2015","unstructured":"Tamma PD, Han JH, Rock C, Harris AD, Lautenbach E, Hsu AJ, et al. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum beta-lactamase bacteremia. Clin Infect Dis. 2015;60:1319\u201325.","journal-title":"Clin Infect Dis"},{"key":"1320_CR35","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","volume":"60","author":"J Solomkin","year":"2015","unstructured":"Solomkin J, Hershberger E, Miller B, Popejoy M, Friedland I, Steenbergen J, et al. Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis. 2015;60:1462\u201371.","journal-title":"Clin Infect Dis"},{"key":"1320_CR36","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","volume":"385","author":"FM Wagenlehner","year":"2015","unstructured":"Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet. 2015;385:1949\u201356.","journal-title":"Lancet"},{"key":"1320_CR37","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1473-3099(14)70950-8","volume":"15","author":"PN Harris","year":"2015","unstructured":"Harris PN, Tambyah PA, Paterson DL. beta-lactam and beta-lactamase inhibitor combinations in the treatment of extended-spectrum beta-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? Lancet Infect Dis. 2015;15:475\u201385.","journal-title":"Lancet Infect Dis"},{"key":"1320_CR38","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/cid\/cis916","volume":"56","author":"NY Lee","year":"2013","unstructured":"Lee NY, Lee CC, Huang WH, Tsui KC, Hsueh PR, Ko WC. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters. Clin Infect Dis. 2013;56:488\u201395.","journal-title":"Clin Infect Dis"},{"key":"1320_CR39","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/jac\/dkt450","volume":"69","author":"HM Nguyen","year":"2014","unstructured":"Nguyen HM, Shier KL, Graber CJ. Determining a clinical framework for use of cefepime and beta-lactam\/beta-lactamase inhibitors in the treatment of infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother. 2014;69:871\u201380.","journal-title":"J Antimicrob Chemother"},{"key":"1320_CR40","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/jac\/dkq108","volume":"65","author":"EB Hirsch","year":"2010","unstructured":"Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother. 2010;65:1119\u201325.","journal-title":"J Antimicrob Chemother"},{"key":"1320_CR41","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1469-0691.2011.03553.x","volume":"17","author":"GL Daikos","year":"2011","unstructured":"Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect. 2011;17:1135\u201341.","journal-title":"Clin Microbiol Infect"},{"key":"1320_CR42","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1128\/AAC.02166-13","volume":"58","author":"GL Daikos","year":"2014","unstructured":"Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58:2322\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"1320_CR43","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1093\/jac\/dku168","volume":"69","author":"M Paul","year":"2014","unstructured":"Paul M, Carmeli Y, Durante-Mangoni E, Mouton JW, Tacconelli E, Theuretzbacher U, et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother. 2014;69:2305\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"1320_CR44","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1097\/CCM.0000000000001249","volume":"43","author":"JL Vincent","year":"2015","unstructured":"Vincent JL, Brealey D, Libert N, Abidi NE, O'Dwyer M, Zacharowski K, et al. Rapid diagnosis of infection in the critically ill, a multicenter study of molecular detection in bloodstream infections, pneumonia, and sterile site infections. Crit Care Med. 2015;43:2283\u201391.","journal-title":"Crit Care Med"},{"key":"1320_CR45","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1097\/CCM.0000000000001028","volume":"43","author":"MJ Dautzenberg","year":"2015","unstructured":"Dautzenberg MJ, Wekesa AN, Gniadkowski M, Antoniadou A, Giamarellou H, Petrikkos GL, et al. The association between colonization with carbapenemase-producing enterobacteriaceae and overall ICU mortality: an observational cohort study. Crit Care Med. 2015;43:1170\u20137.","journal-title":"Crit Care Med"},{"key":"1320_CR46","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/cid\/ciu1173","volume":"60","author":"MK Hayden","year":"2015","unstructured":"Hayden MK, Lin MY, Lolans K, Weiner S, Blom D, Moore NM, et al. Prevention of colonization and infection by Klebsiella pneumoniae carbapenemase-producing enterobacteriaceae in long-term acute-care hospitals. Clin Infect Dis. 2015;60:1153\u201361.","journal-title":"Clin Infect Dis"},{"key":"1320_CR47","first-page":"89","volume-title":"Antibiotic therapy and control of antimicrobial resistance in hospitals","author":"JP Burke","year":"1999","unstructured":"Burke JP, Pestotnik SL. Computer-assisted prescribing and its impact on resistance. In: Andremont A, Brun-Buisson C, McGowan Jr JE, editors. Antibiotic therapy and control of antimicrobial resistance in hospitals. Paris: Elsevier; 1999. p. 89\u201395."},{"key":"1320_CR48","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/jac\/dkl097","volume":"57","author":"A Sandiumenge","year":"2006","unstructured":"Sandiumenge A, Diaz E, Rodriguez A, Vidaur L, Canadell L, Olona M, et al. Impact of diversity of antibiotic use on the development of antimicrobial resistance. J Antimicrob Chemother. 2006;57:1197\u2013204.","journal-title":"J Antimicrob Chemother"},{"key":"1320_CR49","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/TA.0b013e318120595e","volume":"63","author":"KM Bennett","year":"2007","unstructured":"Bennett KM, Scarborough JE, Sharpe M, Dodds-Ashley E, Kaye KS, Hayward III TZ, et al. Implementation of antibiotic rotation protocol improves antibiotic susceptibility profile in a surgical intensive care unit. J Trauma. 2007;63:307\u201311.","journal-title":"J Trauma"},{"key":"1320_CR50","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/510393","volume":"44","author":"TH Dellit","year":"2007","unstructured":"Dellit TH, Owens RC, McGowan Jr JE, Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44:159\u201377.","journal-title":"Clin Infect Dis"},{"key":"1320_CR51","doi-asserted-by":"crossref","first-page":"e1004225","DOI":"10.1371\/journal.ppat.1004225","volume":"10","author":"P Abel zur Wiesch","year":"2014","unstructured":"Abel zur Wiesch P, Kouyos R, Abel S, Viechtbauer W, Bonhoeffer S. Cycling empirical antibiotic therapy in hospitals: meta-analysis and models. PLoS Pathog. 2014;10:e1004225.","journal-title":"PLoS Pathog"},{"key":"1320_CR52","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00134-012-2769-8","volume":"39","author":"RP Dellinger","year":"2013","unstructured":"Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39:165\u2013228.","journal-title":"Intensive Care Med"},{"key":"1320_CR53","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1056\/NEJMoa1411162","volume":"372","author":"RG Sawyer","year":"2015","unstructured":"Sawyer RG, Claridge JA, Nathens AB, Rotstein OD, Duane TM, Evans HL, et al. Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med. 2015;372:1996\u20132005.","journal-title":"N Engl J Med"},{"key":"1320_CR54","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/cid\/cis464","volume":"55","author":"P Schuetz","year":"2012","unstructured":"Schuetz P, Briel M, Christ-Crain M, Stolz D, Bouadma L, Wolff M, et al. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis. 2012;55:651\u201362.","journal-title":"Clin Infect Dis"},{"key":"1320_CR55","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.bbapap.2008.11.005","volume":"1794","author":"AH Delcour","year":"2009","unstructured":"Delcour AH. Outer membrane permeability and antibiotic resistance. Biochim Biophys Acta. 2009;1794:808\u201316.","journal-title":"Biochim Biophys Acta"},{"key":"1320_CR56","doi-asserted-by":"crossref","unstructured":"Hooper DC, Jacoby GA. Mechanisms of drug resistance: quinolone resistance. Ann N Y Acad Sci. 2015;1354:12-31.","DOI":"10.1111\/nyas.12830"},{"key":"1320_CR57","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/jac\/dki171","volume":"56","author":"K Poole","year":"2005","unstructured":"Poole K. Efflux-mediated antimicrobial resistance. J Antimicrob Chemother. 2005;56:20\u201351.","journal-title":"J Antimicrob Chemother"},{"key":"1320_CR58","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1128\/AAC.43.4.727","volume":"43","author":"MP Mingeot-Leclercq","year":"1999","unstructured":"Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. Aminoglycosides: activity and resistance. Antimicrob Agents Chemother. 1999;43:727\u201337.","journal-title":"Antimicrob Agents Chemother"},{"key":"1320_CR59","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1128\/AAC.06187-11","volume":"56","author":"TH Grossman","year":"2012","unstructured":"Grossman TH, Starosta AL, Fyfe C, O'Brien W, Rothstein DM, Mikolajka A, et al. Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother. 2012;56:2559\u201364.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-016-1320-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:26:43Z","timestamp":1748910403000},"score":1,"resource":{"primary":{"URL":"http:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-016-1320-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,22]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1320"],"URL":"https:\/\/doi.org\/10.1186\/s13054-016-1320-7","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,22]]},"article-number":"136"}}